

Table of Contents

ABSTRACT.....	5
ZUSAMMENFASSUNG	7
Chapter 1- Introduction.....	9
1.1 Hematologic malignancies.....	10
1.1.1 Acute Lymphoblastic Leukemia	10
1.1.2 Multiple Myeloma.....	11
1.2 B cell development from hematopoietic progenitors.....	13
1.3 IL-7 receptor signaling pathway	14
1.4 RAS signaling pathway.....	16
1.4.1 RAS structure.....	16
1.4.2 RAS regulation.....	19
1.4.3 RAS effectors.....	20
1.4.4 Targeting the RAS effector signaling pathway as a promising therapeutic avenue.....	23
1.5 Proteostasis in cancer.....	24
1.5.1 Unfolded Protein Response.....	25
1.5.2 IRE1 α -XBP1 axis.....	27
1.5.3 The role of the IRE1 α -XBP1 signaling in cancer	28
1.5.4 Ubiquitin-proteasome system	29
1.5.5 Autophagy.....	31
1.5.6 Autophagy as a therapeutic target in cancer	33
Chapter 2-Materials and Methods.....	35
2.1 Human cell culture.....	36
2.2 Murine cell culture.....	37
2.3 Bacterial cell culture	37
2.4 Cloning and plasmid construction.....	38
2.4.1 Isolation of plasmid DNA from <i>E. coli</i>	38
2.4.2 Polymerase chain reaction	38
2.4.3 Agarose gel electrophoresis	39
2.4.4 DNA restriction digestion	39
2.4.5 DNA ligation.....	40
2.4.6 DNA sequencing.....	40

2.4.7 Transformation of <i>E. coli</i>	40
2.4.8 Bacterial glycerol stock.....	40
2.4.9 Isolation of plasmid DNA	41
2.5 Calcium phosphate transfection of platinum-E for virus production.....	41
2.6 Mouse model of human pre-B NRAS ^{G12D} ALL.....	42
2.6.1 Isolation of genomic DNA from mouse tails for genotyping.....	43
2.6.2 Genotyping.....	43
2.6.3 Harvesting bone marrow from femurs and tibiae	44
2.6.4 Retroviral transduction.....	45
2.6.5 Inducible deletion of the <i>Xbp1</i> floxed gene	46
2.7 Flow Cytometry analysis	46
2.7.1 Cell viability measurement	46
2.7.2 Apoptosis assay.....	47
2.7.3 Cell cycle assay.....	47
2.7.4 Immunophenotyping.....	48
2.8 Western blotting.....	49
2.8.1 Protein extraction.....	49
2.8.2 Determination protein concentration by Bradford assay.....	49
2.8.3 SDS-PAGE (SDS polyacrylamide gel electrophoresis).....	50
2.8.4 Western blotting and immunological detection of protein.....	50
2.8.5 Stripping the membranes	51
2.9 Gene expression analysis	52
2.9.1 RNA extraction	52
2.9.2 cDNA synthesis	53
2.9.3 RT-qPCR.....	54
Chapter 3-Results.....	57
Project I: Interplay between PI3K/AKT signaling and IRE1a-XBP1 promotes survival of pre-B NRAS ^{G12D} ALL cells and targeting XBP1 in pre-B ALL sensitizes cells to PI3K/mTOR inhibitors.....	58
Aim of the study.....	58
3.1.1 Interleukin-7 is a pivotal cytokine for survival of pre-B NRAS ^{G12D} ALL cells.....	59
3.1.2 Targeting the IL-7 signaling pathway activates the Ras-Erk signaling pathway in NRAS ^{G12D} pre-B ALL.....	61
3.1.3 XBP1 promotes pre-B cell acute lymphoblastic leukemia through the IL-7 receptor signaling pathway.....	64
3.1.4 Pharmacological inhibition of <i>Xbp1</i> splicing with MKC8866 is as efficient as genetic loss of <i>Xbp1</i> in NRAS ^{G12D} mutated ALL.....	70

3.1.5 Dual PI3K/MTOR inhibitor has synergistic effect with MKC-8866 against NRAS ^{G12D} pre-B ALL cells	72
Project II: Proteostasis: Crosstalk between Proteasomes, Autophagy and UPR in Multiple Myeloma	80
Aim of the study.....	80
3.2.1 The effect of the Proteasome Inhibitor Ixazomib (MLN9708) and UPR mediated therapy in Multiple Myeloma cells and their bone marrow niche	81
3.2.1.1 Ixazomib strongly reduces cell viability of multiple myeloma cells in combination with IRE1 α inhibitors.....	81
3.2.1.2 Ixazomib in combination with IRE1 α inhibitors slightly increase apoptosis and cause cell cycle arrest in multiple myeloma cells.....	84
3.2.1.3 <i>XBPIs</i> expression is induced by ixazomib treatment under support of MSCs cells.....	87
3.2.2 The effect of the Proteasome Inhibitor ixazomib (MLN9708) and autophagy-mediated cell death in multiple myeloma cells	88
3.2.2.1 Ixazomib in combination with autophagy inhibitors strongly induces apoptosis in MM cells	89
3.2.2.2 Cytotoxicity induced by ixazomib in combination with autophagy inhibitors is mediated via JNK activation.....	92
Chapter 4-Discussion	94
Part I: Interplay between PI3K/AKT signaling and IRE1 α -XBPI promotes survival of pre-B NRAS ^{G12D} ALL cells and targeting XBPI in pre-B ALL sensitizes cells to PI3K/mTOR inhibitors	95
4.1 IRE1 α -XBPI mediated signaling contributes to oncogenic RAS signaling in pre-B cell acute lymphoblastic leukemia (ALL).....	95
4.1.1 The IL-7 receptor signaling pathway counteracts the RAS signaling pathway in pre-B NRAS ^{G12D} ALL cells.....	95
4.1.2 Activation of the UPR positively correlates with Ras-ERK signaling in pre-B NRAS ^{G12D} ALL cells and supports the survival of ALL cells upon activation NRAS ^{G12D}	97
4.1.3 XBPI promotes survival and proliferation of pre-B ALL cells through the IL-7 receptor signaling pathway	98
4.1.4 Pharmacological inhibition of XBPI activation with MKC-8866 synergistically reduced viability of pre-B ALL cells in combination with PI3K/mTOR inhibitor BEZ235.....	100
4.1.5 XBPI signaling and its cooperation with IL-7 receptor and RAS signaling pathways in pre-B ALL.....	102
4.1.6 Conclusion and future perspective.....	104
Part II: Proteostasis: crosstalk between proteasomes, autophagy and UPR in multiple myeloma	107
4.2 Targeting the proteostasis network as a therapeutic strategy in multiple myeloma.....	107
4.2.1 Mechanism of antitumor activity of proteasome inhibitor ixazomib and UPR in multiple myeloma.....	107
4.2.2 Interplay between proteasome pathway and autophagy generates protective effects against of cytotoxic effect of ixazomib in multiple myeloma	109

4.2.3 Crosstalk between ubiquitin-proteasome system, autophagy and UPR in multiple myeloma	110
4.2.4 Conclusion and future perspective	111
Supplementary Data	113
APPENDIX:	116
I: Abbreviations	116
II: Abbreviations	119
References	121
Acknowledgment	135
Publications	136
Eidesstattliche Erklärung	137